| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185134 | Gynecologic Oncology | 2014 | 9 Pages |
Abstract
Trebananib 10Â mg/kg and 15Â mg/kg IV QW plus PLD or topotecan appear to have acceptable toxicity profiles in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Antitumor activity was evident across all cohorts.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Ignace Vergote, Russell J. Schilder, Charles H. Jr., Shirley Wong, Alan N. Gordon, Sidney Scudder, Frederic Kridelka, Luc Dirix, Joseph W. Leach, Sumitra Ananda, Nuwan Nanayakkara, Rebeca Melara, Michael B. Bass, Jason Litten, Henry Adewoye,